Breast Cancer Resources
Breast cancer is the most common cancer diagnosed in the US, and it is also the most common cancer diagnosed worldwide. More specifically, in the US alone, approximately 4 million women are diagnosed with the disease. Breast cancer, like other forms of cancer, is the result of DNA mutations that cause cells to grow at an exponential rate. However, in the case of breast cancer, these DNA mutations target cells in breast tissue.1
AMCP is pleased to work with Novartis to provide you with these resources.
Roundtable on Breast Cancer Resources
This roundtable discussion focuses on the CDK4/6 inhibitors currently approved to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. An oncologist and pharmacist review differences in efficacy and safety among the medications in this class: abemaciclib, palbociclib, and ribociclib. They also discuss new research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology. Topics include recent data on overall survival versus progression-free survival, payer considerations, and the clinical utility of dose modifications with ribociclib.
Ryan Haumschild, PharmD, MS, MBA
Director of Pharmacy
Emory Healthcare and Winship Cancer Institute
Kevin Kalinsky, MD, MS
Department of Hematology and Medical Oncology
Emory University School of Medicine
Sponsored by Novartis
This program was sponsored by Novartis. The views and opinions expressed in this program are those of the participants and speakers and may not reflect the views of AMCP and/or Novartis. The participants in this program were compensated by Novartis for their participation.
1. Boughey, J. (n.d.). What is breast cancer? An expert explains. Mayo Clinic. Retrieved November 17, 2022, from https://www.mayoclinic.org/diseases-conditions/breast-cancer/multimedia/vid-20522464